x

Like our Facebook Page

   
Early Times Newspaper Jammu, Leading Newspaper Jammu
 
Breaking News :   Justice For Terror Victim Families | Kathua Administration welcomes first Batch of Amarnath Yatris at Lakhanpur | Yatra of resilience: LG to flag off first batch today after Pahalgam carnage, Op Sindoor | LG visits Yatri Niwas at Bhagwati Nagar, reviews arrangements | LG reviews final preparations | LG chairs high-level meeting, discusses issues of terror victim families | LG flags off fleet of ambulances in Ramban, Anantnag districts | 5 real brothers from Budgam among fraudulently selected candidates | Hope beneath the surface: Govt plans underground hospital in Poonch | ACB catches DDC member red handed | Crime Branch books J&K Bank officers, others for frauds | Back Issues  
 
news details
Forest fire triggers mine blasts along LoC in Poonch
10/24/2020 12:44:00 AM

EARLY TIMES REPORT

POONCH, Oct, 23: Aforest fire triggered several mine blasts along the Line of Control in Jammu and Kashmir’s Poonch district on Friday, officials said. The fire broke out in Balakot sector and spread to few adjoining areas, they said. Some anti-personnel mines exploded due to the fire, triggering panic among the residents, the officials said. The blaze was brought under control by Army and forest department personnel within a few hours, they said. The Bharat Biotech will be conducting Phase 3 trials for its Covid-19 vaccine candidate, COVAXIN, in 25 centres across India and a total of 26,000 people will be participating in the Phase 3 trials.
The Drug Controller General of India (DGCI) has already granted Bharat Biotech a go ahead for the Phase 3 trials after successful completion of Phase 1 and 2 clinical trials. However, the permission for the Phase 3 trials of COVAXIN is subject to minor changes in the primary efficacy endpoint for the symptomatic cases. The primary efficacy endpoint is the outcome by which the effectiveness of treatments in a clinical trial is evaluated. A carefully chosen endpoint can ensure no bias. A primary efficacy endpoint needs to be specified before the start of the clinical trial. “The firm has presented their data from Phase I and II along with animal challenge data in two species including NHP on the Inactivated Corona Virus Vaccine (BBV152) along with the proposal to conduct event-driven Phase III clinical trial to assess the efficacy of the vaccine,” the expert panel of Subject Expert Committee (SEC) said. Developed by Bharat Biotech along with the Indian Council of Medical Research and National Institute of Virology, Covaxin was India’s first indigenous vaccine candidate against the Covid-19.
  Share This News with Your Friends on Social Network  
  Comment on this Story  
 
 
 
Early Times Android App
STOCK UPDATE
  
BSE Sensex
NSE Nifty
 
CRICKET UPDATE
 
 
 
 
 
 
 
 
   
Home About Us Top Stories Local News National News Sports News Opinion Editorial ET Cetra Advertise with Us ET E-paper
 
 
J&K RELATED WEBSITES
J&K Govt. Official website
Jammu Kashmir Tourism
JKTDC
Mata Vaishnodevi Shrine Board
Shri Amarnath Ji Shrine Board
Shri Shiv Khori Shrine Board
UTILITY
Train Enquiry
IRCTC
Matavaishnodevi
BSNL
Jammu Kashmir Bank
State Bank of India
PUBLIC INTEREST
Passport Department
Income Tax Department
JK CAMPA
JK GAD
IT Education
Web Site Design Services
EDUCATION
Jammu University
Jammu University Results
JKBOSE
Kashmir University
IGNOU Jammu Center
SMVDU